Albendazole - Isotope Labelled Standards
References
FAQ's
References
- Gyurik, Robert J.; Theodorides, Vassilios J., Methyl 5-propylthio-2-benzimidazolecarbamate, Smithkline Corp., United States, US3915986A, October 28, 1975
- Alvinerie, M.; Galtier, P., Simultaneous determination of albendazole and its principal metabolites in plasma by normal phase high-performance liquid chromatography, Journal of Pharmaceutical and Biomedical Analysis, Volume: 2, Issue: 1, Pages: 73-9, 1984
Frequently Asked Questions
What are the challenges in the analysis of Albendazole impurities?
Challenges faced during Albendazole impurity analysis include the sensitivity of analytical methods and the potential variability of impurity levels between batches.
What is the difference between process-related and product-related impurities in Albendazole?
Process-related impurities in Albendazole arise during manufacturing, while degradation impurities occur during the storage or handling of the drug product.
How are Albendazole impurities controlled during the manufacturing of the drug?
Impurities in Albendazole are controlled during manufacturing with process optimization, careful selection of raw materials, and appropriate analytical testing throughout the production process.
What are the temperature conditions required to store Albendazole impurities?
Albendazole impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.